ArticleApoptosis : an international journal on programmed cell death2026
GOLPH3-mediated sialylation of CXCR4 drives malignant progression and M2 macrophage polarization in colorectal cancer.
Article in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Sialylation, a post-translational protein modification, correlates with tumor malignancy. This study investigates how GOLPH3 regulates CXCR4 sialylation in colorectal cancer (CRC) and its impact on cancer cell phenotypes. Predicted glycosylation sites on CXCR4 were identified using the NetNGlyc-1.0 tool. The GOLPH3-CXCR4 interaction and GOLPH3-sialyltransferase associations were bioinformatically predicted (BIOGRAD) and validated experimentally via co-immunoprecipitation (Co-IP). CXCR4 sialylation was assessed by immunoprecipitation (IP) and lectin blotting (LB). Immunohistochemical (IHC) assessment of protein expression levels of Ki-67, GOLPH3, and CD206 in tissues. Functional assays, including colony formation, flow cytometry, scratch, and Transwell assays, evaluated proliferation, apoptosis, migration, and invasion in CRC. A co-culture system, flow cytometry, and Enzyme-Linked Immunosorbent Assay (ELISA) were conducted to assess macrophage M2 polarization, and a xenograft tumor model was constructed for in vivo validation. GOLPH3 promotes the interaction between CXCR4 and its ligand CXCL12 by inducing sialylation at the 180th amino acid residue of CXCR4. This regulatory mechanism plays an important role in modulating macrophage function, which manifests as facilitating cell proliferation, migration and invasion, suppressing cellular apoptosis, and promoting M2-type macrophage polarization. Furthermore, N180 mutation assays offer direct experimental evidence to validate the causal relationship within this regulatory network. These findings reveal a GOLPH3-ST6GAL1 axis that enhances CXCR4 sialylation to drive CRC progression and an immunosuppressive microenvironment via CXCL12/CXCR4 signaling, suggesting a novel regulatory mechanism underlying glycosylation modification of this chemokine receptor.
Indexed as
Identifiers
42749929What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.